ESC 365 - Effect of empagliflozin on epicardial adipose tissue volume in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)

ESC Premium Access

Effect of empagliflozin on epicardial adipose tissue volume in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)

Session: Obesity and heart failure: what's new?

Topic: Imaging

Speaker: Ms C. Turgut (Glasgow, GB)

Event: ESC Congress 2024

Congress Presentation

About the speaker

Ms Ceren Turgut

Glasgow (United Kingdom of Great Britain & Northern Ireland)

0 follower

7 more presentations in this session

In-hospital economic impact and mortality of bariatric surgery on congestive heart failure in the USA: a nationwide analysis

Speaker: Doctor S. Sinclair (Yankton, US)

What characterizes normotensive individuals with obesity and normal systolic heart function? A descriptive study from the SCAPIS cohort

Speaker: Doctor J. Korduner (Lund, SE)

Effects of body mass index on worsening of heart failure and all-cause death in patients with heart failure and reduced left ventricular ejection fraction: a 10-year follow-up study

Speaker: Mr M. Malmborg (Herlev, DK)

Association of epicardial adipose tissue with cardiac geometry alternation and diastolic dysfunction in the early stage of diabetic cardiomyopathy

Speaker: Doctor J. Hsu (New Taipei City, TW)

Epicardial adipose tissue volume and density are associated with heart failure with improved ejection fraction

Speaker: Doctor C. Yang (Shanghai, CN)

Access the full session

Obesity and heart failure: what's new?

Speakers: Ms C. Turgut, Doctor S. Sinclair, Doctor J. Korduner, Mr M. Malmborg, Doctor J. Hsu...

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources